Tribute Pharmaceuticals Receives Uracyst(R) Patent in Europe

MILTON, ONTARIO--(Marketwired - Oct. 30, 2014) - Tribute Pharmaceuticals Canada Inc. (OTCQX:TBUFF)(TSX VENTURE:TRX) ("Tribute" or the "Company"), today announced that it has received a patent approval from the European Patent Office ("EPO") for intellectual property central to one of the Company's lead products, Uracyst^®/Uropol^® (a sterile sodium chondroitin sulfate solution, 2%), for the treatment of interstitial cystitis by instillation into the bladder of a patient. Treatments of other bladder disorders are also covered by the patent, including glycosaminoglycan ("GAG") deficient forms of cystitis or GAG-deficiency, such as, accompanying chronic urinary tract infection, radiation- induced cystitis, chemical-induced cystitis or hemorrhagic cystitis. The European patent coverage extends to drug compositions comprising a unit dose of chondroitin sulfate in an amount of at least 400 mgs and an aqueous vehicle. This patent will run until February 18, 2024.

The European Patent No. 1603578, entitled "Treatment of Interstitial Cystitis with High Dose Chondroitin Sulphate", will be the 9^th high dose patent granted on Uracyst®/Uropol® around the world. Currently, the Company has high dose patents granted in the United States (4), Canada, Japan, Australia and China. There are also high dose patents pending in several other countries.

Rob Harris, Tribute's President and Chief Executive Officer, commented, "This European patent was granted just weeks after the 4^th U.S. patent was issued and further expands the scope of Tribute's exclusive rights in Europe for Uracyst^®/Uropol^® and further validates the innovative nature of Tribute's approach to the treatment of interstitial cystitis / bladder pain syndrome ("IC/BPS")." Mr. Harris further stated, "Uracyst^®/Uropol^® are sold extensively throughout Europe by Tribute's partners and this patent approval will have significant meaning to each of them. The Company is also developing plans to maximize the value of this unique product in the U.S. and other territories throughout the world where Uracyst^®/Uropol^® are currently not marketed."

About Uracyst^®

According to published literature, up to 70% of IC patients have defects in their bladder GAG layers. The GAG layer is a mucosal lining of the bladder that acts as a protective barrier against irritants and toxins in the urine and defends against bacterial adherence. When the GAG layer is damaged, these irritants and toxins in the urine seep through, causing an irritation to the bladder wall. This results in increased frequency and urgency to void (up to 60 times a day). Many IC/BPS patients also experience severe pelvic pain. These symptoms can be debilitating and have a serious impact on a patient's quality of life.